文献速递神经肿瘤

CBTRUS统计报告:2014-2018年美国原发性脑及其他中枢神经系统肿瘤诊断数据

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.
PubMed 文献 · Neuro Oncol · 2021-01-01

CBTRUS联合CDC和NCI发布2014-2018年美国原发性脑及中枢神经系统肿瘤的基于人群统计报告,首次提供部分肿瘤组织学的分子标志物分布。所有恶性肿瘤和非恶性肿瘤的平均年年龄调整发病率为24.25/10万,其中恶性为7.06/10万,非恶性为17.18/10万。胶质母细胞瘤是最常见的恶性肿瘤(占所有肿瘤14.3%,占恶性肿瘤49.1%),脑膜瘤是最常见的非恶性肿瘤(占所有肿瘤39%,占非恶性肿瘤54.5%)。

要点

  • 女性总体发病率高于男性(26.95 vs 21.35/10万),非西班牙裔高于西班牙裔(24.68 vs 22.12/10万)。
  • 儿童青少年(0-19岁)原发性脑及中枢神经系统肿瘤发病率为6.21/10万。
  • 恶性脑及中枢神经系统肿瘤5年相对生存率为66.9%,非恶性为92.1%。

核心结论

  • 2014-2018年美国脑及中枢神经系统肿瘤平均年年龄调整发病率为24.25/10万,其中恶性7.06/10万,非恶性17.18/10万。

研究设计与样本

  • CBTRUS与CDC和NCI合作,基于覆盖全美人群的最大原发性脑及中枢神经系统肿瘤登记数据进行分析。

主要发现

  • 胶质母细胞瘤占所有肿瘤的14.3%、占恶性肿瘤的49.1%,在男性中更常见。
  • 脑膜瘤占所有肿瘤的39%、占非恶性肿瘤的54.5%,在女性中更常见。
  • 2014-2018年间恶性脑及中枢神经系统肿瘤死亡83,029例,平均年死亡率4.43/10万,年均死亡16,606例。
  • 估计2021年美国将新诊断88,190例脑及中枢神经系统肿瘤(恶性25,690例,非恶性62,500例)。

关键数值与推荐

  • 所有率均按2000年美国标准人口进行年龄调整,以每10万人口表示。
  • 总体发病率女性高于男性(26.95 vs 21.35),非西班牙裔高于西班牙裔(24.68 vs 22.12)。
  • 儿童青少年(0-19岁)原发性脑及中枢神经系统肿瘤发病率为6.21/10万。
  • 恶性脑及中枢神经系统肿瘤5年相对生存率66.9%,非恶性为92.1%。

临床怎么用

  • 可为神经外科医生提供美国脑及中枢神经系统肿瘤的流行病学基线,用于疾病负担评估和资源规划。
  • 分子标志物分布数据有助于理解特定组织学类型的分子特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the CDC and NCI, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy and is the first CBTRUS Report to provide the distribution of molecular markers for selected brain and CNS tumor histologies. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.25 (Malignant AAAIR=7.06, Non-malignant AAAIR=17.18). This overall rate was higher in females compared to males (26.95 versus 21.35) and non-Hispanics compared to Hispanics (24.68 versus 22.12). The most commonly occurring malignant brain and other CNS tumor was glioblastoma (14.3% of all tumors and 49.1% of malignant tumors), and the most common non-malignant tumor was meningioma (39% of all tumors and 54.5% of non-malignant tumors). Glioblastoma was more common in males, and meningioma was more common in females. In children and adolescents (age 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.21. An estimated 88,190 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US population in 2021 (25,690 malignant and 62,500 non-malignant). There were 83,029 deaths attributed to malignant brain and other CNS tumors between 2014 and 2018. This represents an average annual mortality rate of 4.43 per 100,000 and an average of 16,606 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 66.9%, for a non-malignant brain and other CNS tumors the five-year relative survival rate was 92.1%.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ostrom QT, Cioffi G, Waite K, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. Neuro Oncol. 2021. PMID: 34608945. doi:10.1093/neuonc/noab200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。